Clinical Trial

Chinese Spondyloarthritis Inception Cohort (CESPIC)

Study acronym: CESPIC
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). CESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: reactive arthritis, acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-25; most recent amendment 2024-04-16.
Trial Details
NCT Number NCT05960864
Lead Sponsor Southwest Hospital, China
Conditions Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Axial Psoriatic Arthritis (axPsA), Acute Anterior Uveitis (AAU), Crohn Disease (CD), Ulcerative Colitis (UC), Reactive Arthritis (ReA)
Enrollment 1,000 participants
Start Date 2024-09
Primary Completion 2025-08 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2024-04-17